UniQure saw the highest growth of 1.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of UniQure‘s patent filings and grants. Buy the databook here.
UniQure has been focused on protecting inventions in European Patent Office(EPO) with six publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings and grants with nearly 67% filings and 33% grants. The European Patent Office(EPO), United States(US), and Canada(CA) patent Office are among the top ten patent offices where UniQure is filings its patents. Among the top granted patent authorities, UniQure has 67% of its grants in Canada(CA) and 33% in European Patent Office(EPO).
University of Pennsylvania could be the strongest competitor for UniQure
Patents related to cell & gene therapy and genomics lead UniQure's portfolio
UniQure has the highest number of patents in cell & gene therapy followed by, genomics and rare diseases. For cell & gene therapy, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Cryopyrin-associated periodic syndromes related patents lead UniQure portfolio followed by hemophilia, and hemorrhage
UniQure has highest number of patents in cryopyrin-associated periodic syndromes followed by hemophilia, hemorrhage, osteoarthritis, and cyst.
For comprehensive analysis of UniQure's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.